研究成果

  1. Park H, Yamaguchi R, Imoto S, Miyano S. Xprediction: Explainable EGFR-TKIs response prediction based on drug sensitivity specific gene networks. PLoS One. In press.

  2. Park H, Yamaguchi R, Imoto S, Miyano S. Uncovering molecular mechanisms of drug resistance via network-constrained common structure identification. J Comput Biol. In press.

  3. Saiki R, Momozawa Y, Nannya Y, Nakagawa MM, Ochi Y, Yoshizato T, Terao C, Kuroda Y, Shiraishi Y, Chiba K, Tanaka H, Niida A, Imoto S, Matsuda K, Morisaki T, Murakami Y, Kamatani Y, Matsuda S, Kubo M, Miyano S, Makishima H, Ogawa S. Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis. Nat Med. 2021 Jul;27(7):1239-1249. doi: 10.1038/s41591-021-01411-9. Epub 2021 Jul 8.

  4. Fujii Y, Sato Y, Suzuki H, Kakiuchi N, Yoshizato T, Lenis AT, Maekawa S, Yokoyama A, Takeuchi Y, Inoue Y, Ochi Y, Shiozawa Y, Aoki K, Yoshida K, Kataoka K, Nakagawa MM, Nannya Y, Makishima H, Miyakawa J, Kawai T, Morikawa T, Shiraishi Y, Chiba K, Tanaka H, Nagae G, Sanada M, Sugihara E, Sato TA, Nakagawa T, Fukayama M, Ushiku T, Aburatani H, Miyano S, Coleman JA, Homma Y, Solit DB, Kume H, Ogawa S. Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell. 2021 Jun 14;39(6):793-809.e8. doi: 10.1016/j.ccell.2021.05.008.

  5. Mizumaki H, Hosomichi K, Hosokawa K, Yoroidaka T, Imi T, Zaimoku Y, Katagiri T, Anh Thi Nguyen M, Cao Tran D, Ibrahim Yousef Elbadry M, Chonabayashi K, Yoshida Y, Takamatsu H, Ozawa T, Azuma F, Kishi H, Fujii Y, Ogawa S, Tajima A, Nakao S. A frequent nonsense mutation in exon 1 across certain HLA-A and -B alleles in leukocytes of patients with acquired aplastic anemia. Haematologica. 2021 Jun 1;106(6):1581-1590. doi: 10.3324/haematol.2020.247809.

  6. Nakamura F, Arai H, Nannya Y, Ichikawa M, Furuichi S, Nagasawa F, Takahashi W, Handa T, Nakamura Y, Tanaka H, Nakamura Y, Sasaki K, Miyano S, Ogawa S, Mitani K. Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy. Int J Hematol. 2021 Jun;113(6):936-940. doi: 10.1007/s12185-020-03074-7.

  7. Ishida Y, Kakiuchi N, Yoshida K, Inoue Y, Irie H, Kataoka TR, Hirata M, Funakoshi T, Matsushita S, Hata H, Uchi H, Yamamoto Y, Fujisawa Y, Fujimura T, Saiki R, Takeuchi K, Shiraishi Y, Chiba K, Tanaka H, Otsuka A, Miyano S, Kabashima K, Ogawa S. Unbiased Detection of Driver Mutations in Extramammary Paget Disease. Clin Cancer Res. 2021 Mar 15;27(6):1756-1765. doi: 10.1158/1078-0432.CCR-20-3205.

  8. Kaburagi T, Yamato G, Shiba N, Yoshida K, Hara Y, Tabuchi K, Shiraishi Y, Ohki K, Sotomatsu M, Arakawa H, Matsuo H, Shimada A, Taki T, Kiyokawa N, Tomizawa D, Horibe K, Miyano S, Taga T, Adachi S, Ogawa S, Hayashi Y. Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia. Haematologica. 2021 Mar 18. doi: 10.3324/haematol.2020.269431.

  9. Klimkowska M, Nannya Y, Gran C, Månsson R, Douagi I, Ogawa S, Nahi H, Tobiasson M. Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder. Blood. 2021 Mar 4;137(9):1260-1263. doi: 10.1182/blood.2020007555.

  10. Ochi Y, Ogawa S. Chromatin-Spliceosome Mutations in Acute Myeloid Leukemia. Cancers (Basel). 2021 Mar 11;13(6):1232. doi: 10.3390/cancers13061232.

  11. Okabe M, Morishita T, Yasuda T, Sakaguchi H, Sanada M, Kataoka K, Ogawa S, Shiraishi Y, Ichiki T, Kawaguchi Y, Ohbiki M, Matsumoto R, Osaki M, Goto T, Ozawa Y, Miyamura K. Targeted deep next generation sequencing identifies potential somatic and germline variants for predisposition to familial Burkitt lymphoma. Eur J Haematol. 2021 Mar 27. doi: 10.1111/ejh.13629.

  12. Hosokawa K, Mizumaki H, Yoroidaka T, Maruyama H, Imi T, Tsuji N, Urushihara R, Tanabe M, Zaimoku Y, Nguyen MAT, Tran DC, Ishiyama K, Yamazaki H, Katagiri T, Takamatsu H, Hosomichi K, Tajima A, Azuma F, Ogawa S, Nakao S. HLA class I allele-lacking leukocytes predict rare clonal evolution to MDS/AML in patients with acquired aplastic anemia. Blood. 2021 Mar 22:blood.2020010586. doi: 10.1182/blood.2020010586.

  13. Nishimura A, Hirabayashi S, Hasegawa D, Yoshida K, Shiraishi Y, Ashiarai M, Hosoya Y, Fujiwara T, Harigae H, Miyano S, Ogawa S, Manabe A. Acquisition of monosomy 7 and a RUNX1 mutation in Pearson syndrome. Pediatr Blood Cancer. 2021 Feb;68(2):e28799. doi: 10.1002/pbc.28799.

  14. Boons E, Nogueira TC, Dierckx T, Menezes SM, Jacquemyn M, Tamir S, Landesman Y, Farré L, Bittencourt A, Kataoka K, Ogawa S, Snoeck R, Andrei G, Van Weyenbergh J, Daelemans D. XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis. Blood Cancer J. 2021 Feb 1;11(2):27. doi: 10.1038/s41408-021-00409-3.

  15. Li X, Kim W, Arif M, Gao C, Hober A, Kotol D, Strandberg L, Forsström B, Sivertsson Å, Oksvold P, Turkez H, Grøtli M, Sato Y, Kume H, Ogawa S, Boren J, Nielsen J, Uhlen M, Zhang C, Mardinoglu A. Discovery of Functional Alternatively Spliced PKM Transcripts in Human Cancers. Cancers (Basel). 2021 Jan 19;13(2):348. doi: 10.3390/cancers13020348.

  16. Kimura S, Sekiguchi M, Watanabe K, Hiwatarai M, Seki M, Yoshida K, Isobe T, Shiozawa Y, Suzuki H, Hoshino N, Hayashi Y, Oka A, Miyano S, Ogawa S, Takita J. Association of high-risk neuroblastoma classification based on expression profiles with differentiation and metabolism. PLoS One. 2021 Jan 19;16(1):e0245526. doi: 10.1371/journal.pone.0245526.

  17. Fujishima N, Kohmaru J, Koyota S, Kuba K, Saga T, Omokawa A, Moritoki Y, Ueki S, Ishida F, Nakao S, Matsuda A, Ohta A, Tohyama K, Yamasaki H, Usuki K, Nakashima Y, Sato S, Miyazaki Y, Nannya Y, Ogawa S, Sawada K, Mitani K, Hirokawa M. Clonal hematopoiesis in adult pure red cell aplasia. Sci Rep. 2021 Jan 26;11(1):2253. doi: 10.1038/s41598-021-81890-5.

  18. Park H, Maruhashi K, Yamaguchi R, Imoto S, Miyano S. Global gene network exploration based on explainable artificial intelligence approach. PLoS One. 2020 Nov 6;15(11):e0241508. doi: 10.1371/journal.pone.0241508. Erratum in: PLoS One. 2021 Jan 27;16(1):e0246380.

  19. Todisco G, Creignou M, Gallì A, Guglielmelli P, Rumi E, Roncador M, Rizzo E, Nannya Y, Pietra D, Elena C, Bono E, Molteni E, Rosti V, Catricalá S, Sarchi M, Dimitriou M, Ungerstedt J, Vannucchi AM, Hellström-Lindberg E, Ogawa S, Cazzola M, Malcovati L. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms. Leukemia. 2020 Dec 21. doi: 10.1038/s41375-020-01106-z.

  20. Kanamori T, Sanada M, Ri M, Ueno H, Nishijima D, Yasuda T, Tachita T, Narita T, Kusumoto S, Inagaki A, Ishihara R, Murakami Y, Kobayashi N, Shiozawa Y, Yoshida K, Nakagawa MM, Nannya Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Horibe K, Handa H, Ogawa S, Iida S. Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort. Br J Haematol. 2020 Dec;191(5):755-763. doi: 10.1111/bjh.16720.

  21. Fukumoto K, Sakata-Yanagimoto M, Fujisawa M, Sakamoto T, Miyoshi H, Suehara Y, Nguyen TB, Suma S, Yanagimoto S, Shiraishi Y, Chiba K, Bouska A, Kataoka K, Ogawa S, Iqbal J, Ohshima K, Chiba S. VAV1 mutations contribute to development of T-cell neoplasms in mice. Blood. 2020 Dec 24;136(26):3018-3032. doi: 10.1182/blood.2020006513.

  22. Dingler FA, Wang M, Mu A, Millington CL, Oberbeck N, Watcham S, Pontel LB, Kamimae-Lanning AN, Langevin F, Nadler C, Cordell RL, Monks PS, Yu R, Wilson NK, Hira A, Yoshida K, Mori M, Okamoto Y, Okuno Y, Muramatsu H, Shiraishi Y, Kobayashi M, Moriguchi T, Osumi T, Kato M, Miyano S, Ito E, Kojima S, Yabe H, Yabe M, Matsuo K, Ogawa S, Göttgens B, Hodskinson MRG, Takata M, Patel KJ. Two Aldehyde Clearance Systems Are Essential to Prevent Lethal Formaldehyde Accumulation in Mice and Humans. Mol Cell. 2020 Dec 17;80(6):996-1012.e9. doi: 10.1016/j.molcel.2020.10.012.

  23. Ogura H, Ohga S, Aoki T, Utsugisawa T, Takahashi H, Iwai A, Watanabe K, Okuno Y, Yoshida K, Ogawa S, Miyano S, Kojima S, Yamamoto T, Yamamoto-Shimojima K, Kanno H. Novel COL4A1 mutations identified in infants with congenital hemolytic anemia in association with brain malformations. Hum Genome Var. 2020 Nov 27;7(1):42. doi: 10.1038/s41439-020-00130-w.

  24. Ueno H, Yoshida K, Shiozawa Y, Nannya Y, Iijima-Yamashita Y, Kiyokawa N, Shiraishi Y, Chiba K, Tanaka H, Isobe T, Seki M, Kimura S, Makishima H, Nakagawa MM, Kakiuchi N, Kataoka K, Yoshizato T, Nishijima D, Deguchi T, Ohki K, Sato A, Takahashi H, Hashii Y, Tokimasa S, Hara J, Kosaka Y, Kato K, Inukai T, Takita J, Imamura T, Miyano S, Manabe A, Horibe K, Ogawa S, Sanada M. Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. Blood Adv. 2020 Oct 27;4(20):5165-5173. doi: 10.1182/bloodadvances.2019001307.

  25. Matsuo H, Yoshida K, Nakatani K, Harata Y, Higashitani M, Ito Y, Kamikubo Y, Shiozawa Y, Shiraishi Y, Chiba K, Tanaka H, Okada A, Nannya Y, Takeda J, Ueno H, Kiyokawa N, Tomizawa D, Taga T, Tawa A, Miyano S, Meggendorfer M, Haferlach C, Ogawa S, Adachi S. Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML. Blood Adv. 2020 Oct 13;4(19):4623-4631. doi: 10.1182/bloodadvances.2020002457.

  26. Inagaki-Kawata Y, Yoshida K, Kawaguchi-Sakita N, Kawashima M, Nishimura T, Senda N, Shiozawa Y, Takeuchi Y, Inoue Y, Sato-Otsubo A, Fujii Y, Nannya Y, Suzuki E, Takada M, Tanaka H, Shiraishi Y, Chiba K, Kataoka Y, Torii M, Yoshibayashi H, Yamagami K, Okamura R, Moriguchi Y, Kato H, Tsuyuki S, Yamauchi A, Suwa H, Inamoto T, Miyano S, Ogawa S, Toi M. Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants. Commun Biol. 2020 Oct 16;3(1):578. doi: 10.1038/s42003-020-01301-9.

  27. Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, Haase D, Creignou M, Germing U, Zhang Y, Gundem G, Sarian A, van de Loosdrecht AA, Jädersten M, Tobiasson M, Kosmider O, Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I, Boultwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T, Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo L, Sanz G, Ades L, Della Porta MG, Elias HK, Smith AG, Werner Y, Patel M, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellström-Lindberg E, Ogawa S, Papaemmanuil E. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020 Oct;26(10):1549-1556. doi: 10.1038/s41591-020-1008-z.

  28. Yasuda T, Sanada M, Nishijima D, Kanamori T, Iijima Y, Hattori H, Saito A, Miyoshi H, Ishikawa Y, Asou N, Usuki K, Hirabayashi S, Kato M, Ri M, Handa H, Ishida T, Shibayama H, Abe M, Iriyama C, Karube K, Nishikori M, Ohshima K, Kataoka K, Yoshida K, Shiraishi Y, Goto H, Adachi S, Kobayashi R, Kiyoi H, Miyazaki Y, Ogawa S, Kurahashi H, Yokoyama H, Manabe A, Iida S, Tomita A, Horibe K. Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility study. Cancer Sci. 2020 Sep;111(9):3367-3378. doi: 10.1111/cas.14552.

  29. Yokoyama A, Kakiuchi N, Yoshizato T, Muto M, Ogawa S. [How Does Aging Contribute to Cancer?]. Gan To Kagaku Ryoho. 2020 Sep;47(9):1281-1286.

  30. Miyazaki K, Watanabe H, Yoshikawa G, Chen K, Hidaka R, Aitani Y, Osawa K, Takeda R, Ochi Y, Tani-Ichi S, Uehata T, Takeuchi O, Ikuta K, Ogawa S, Kondoh G, Lin YC, Ogata H, Miyazaki M. The transcription factor E2A activates multiple enhancers that drive Rag expression in developing T and B cells. Sci Immunol. 2020 Sep 4;5(51):eabb1455. doi: 10.1126/sciimmunol.abb1455.

  31. Kubota Y, Seki M, Kawai T, Isobe T, Yoshida M, Sekiguchi M, Kimura S, Watanabe K, Sato-Otsubo A, Yoshida K, Suzuki H, Kataoka K, Fujii Y, Shiraishi Y, Chiba K, Tanaka H, Hiwatari M, Oka A, Hayashi Y, Miyano S, Ogawa S, Hata K, Tanaka Y, Takita J. Comprehensive genetic analysis of pediatric germ cell tumors identifies potential drug targets. Commun Biol. 2020 Sep 30;3(1):544. doi: 10.1038/s42003-020-01267-8.

  32. Shirai R, Osumi T, Terashima K, Kiyotani C, Uchiyama M, Tsujimoto S, Yoshida M, Yoshida K, Uchiyama T, Tomizawa D, Shioda Y, Sekiguchi M, Watanabe K, Keino D, Ueno-Yokohata H, Ohki K, Takita J, Ito S, Deguchi T, Kiyokawa N, Ogiwara H, Hishiki T, Ogawa S, Okita H, Matsumoto K, Yoshioka T, Kato M. High prevalence of SMARCB1 constitutional abnormalities including mosaicism in malignant rhabdoid tumors. Eur J Hum Genet. 2020 Aug;28(8):1124-1128. doi: 10.1038/s41431-020-0614-z.

  33. Jo T, Nishikori M, Kogure Y, Arima H, Sasaki K, Sasaki Y, Nakagawa T, Iwai F, Momose S, Shiraishi A, Kiyonari H, Kagaya N, Onuki T, Shin-Ya K, Yoshida M, Kataoka K, Ogawa S, Iwai K, Takaori-Kondo A. LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells. Blood. 2020 Aug 6;136(6):684-697. doi: 10.1182/blood.2019002654.

  34. Sekiguchi M, Seki M, Kawai T, Yoshida K, Yoshida M, Isobe T, Hoshino N, Shirai R, Tanaka M, Souzaki R, Watanabe K, Arakawa Y, Nannya Y, Suzuki H, Fujii Y, Kataoka K, Shiraishi Y, Chiba K, Tanaka H, Shimamura T, Sato Y, Sato-Otsubo A, Kimura S, Kubota Y, Hiwatari M, Koh K, Hayashi Y, Kanamori Y, Kasahara M, Kohashi K, Kato M, Yoshioka T, Matsumoto K, Oka A, Taguchi T, Sanada M, Tanaka Y, Miyano S, Hata K, Ogawa S, Takita J. Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets. NPJ Precis Oncol. 2020 Jul 7;4:20. doi: 10.1038/s41698-020-0125-y.

  35. Okano T, Imai K, Naruto T, Okada S, Yamashita M, Yeh TW, Ono S, Tanaka K, Okamoto K, Tanita K, Matsumoto K, Toyofuku E, Kumaki-Matsumoto E, Okamura M, Ueno H, Ogawa S, Ohara O, Takagi M, Kanegane H, Morio T. Whole-Exome Sequencing-Based Approach for Germline Mutations in Patients with Inborn Errors of Immunity. J Clin Immunol. 2020 Jul;40(5):729-740. doi: 10.1007/s10875-020-00798-3.

  36. Nguyen MAT, Hosokawa K, Yoroidaka T, Maruyama H, Espinoza JL, Elbadry MI, Mohiuddin M, Tanabe M, Katagiri T, Nakagawa N, Chonabayashi K, Yoshida Y, Arima N, Kashiwase K, Saji H, Ogawa S, Nakao S. Resistance of KIR Ligand-Missing Leukocytes to NK Cells In Vivo in Patients with Acquired Aplastic Anemia. Immunohorizons. 2020 Jul 17;4(7):430-441. doi: 10.4049/immunohorizons.2000046.

  37. Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, Maciejewski JP, Walter MJ, Fontenay M, Garcia-Manero G, Graubert TA, Karsan A, Meggendorfer M, Pellagatti A, Sallman DA, Savona MR, Sekeres MA, Steensma DP, Tauro S, Thol F, Vyas P, Van de Loosdrecht AA, Haase D, Tüchler H, Greenberg PL, Ogawa S, Hellstrom-Lindberg E, Cazzola M. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020 Jul 9;136(2):157-170. doi: 10.1182/blood.2020004850.

  38. Katagiri S, Makishima H, Azuma K, Nannya Y, Saitoh Y, Yoshizawa S, Akahane D, Fujimoto H, Ito Y, Velaga R, Umezu T, Ohyashiki JH, Ogawa S, Ohyashiki K. Predisposed genomic instability in pre-treatment bone marrow evolves to therapy-related myeloid neoplasms in malignant lymphoma. Haematologica. 2020 Jul;105(7):e337-e339. doi: 10.3324/haematol.2019.229856.

  39. Maruhashi K, Park H, Yamaguchi R, Miyano S, Linear Tensor Projection Revealing Nonlinearity. arXiv 2020 Jul 8;2007.03912

  40. Nguyen TB, Sakata-Yanagimoto M, Fujisawa M, Nuhat ST, Miyoshi H, Nannya Y, Hashimoto K, Fukumoto K, Bernard OA, Kiyoki Y, Ishitsuka K, Momose H, Sukegawa S, Shinagawa A, Suyama T, Sato Y, Nishikii H, Obara N, Kusakabe M, Yanagimoto S, Ogawa S, Ohshima K, Chiba S. Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma. Cancer Res. 2020 May 1;80(9):1875-1884. doi: 10.1158/0008-5472.CAN-19-2787.

  41. Secardin L, Limia CEG, di Stefano A, Bonamino MH, Saliba J, Kataoka K, Rehen SK, Raslova H, Marty C, Ogawa S, Vainchenker W, Monte-Mor BDCR, Plo I. TET2 haploinsufficiency alters reprogramming into induced pluripotent stem cells. Stem Cell Res. 2020 Apr;44:101755. doi: 10.1016/j.scr.2020.101755.

  42. Kimura S, Seki M, Kawai T, Goto H, Yoshida K, Isobe T, Sekiguchi M, Watanabe K, Kubota Y, Nannya Y, Ueno H, Shiozawa Y, Suzuki H, Shiraishi Y, Ohki K, Kato M, Koh K, Kobayashi R, Deguchi T, Hashii Y, Imamura T, Sato A, Kiyokawa N, Manabe A, Sanada M, Mansour MR, Ohara A, Horibe K, Kobayashi M, Oka A, Hayashi Y, Miyano S, Hata K, Ogawa S, Takita J. DNA methylation-based classification reveals difference between pediatric T-cell acute lymphoblastic leukemia and normal thymocytes. Leukemia. 2020 Apr;34(4):1163-1168. doi: 10.1038/s41375-019-0626-2.

  43. Hashimoto M, Itonaga H, Nannya Y, Taniguchi H, Fukuda Y, Furumoto T, Fujioka M, Kasai S, Taguchi M, Taniguchi H, Sato S, Sawayama Y, Atogami S, Iwasaki K, Hata T, Soda H, Moriuchi Y, Nakata K, Ogawa S, Miyazaki Y. Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome. Intern Med. 2020 Apr 15;59(8):1081-1086. doi: 10.2169/internalmedicine.3770-19.

  44. Imataki O, Ishida T, Kubo H, Uemura M, Nanya Y, Kawakami K, Ogawa S, Kadowaki N. A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation. Case Rep Oncol. 2020 Apr 22;13(1):449-455. doi: 10.1159/000506452.